- Conditions
- Obesity, Weight Loss, Overweight and Obesity
- Interventions
- RZL-012, Placebo
- Drug
- Lead sponsor
- Raziel Therapeutics Ltd.
- Industry
- Eligibility
- 20 Years to 60 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,146
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Optic Neuritis
- Interventions
- Efgartigimod Alfa, Placebo
- Drug
- Lead sponsor
- Anastasia Vishnevetsky, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Obexelimab, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 32
- States / cities
- Peoria, Arizona • Fresno, California • Huntington Park, California + 28 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Telitacicept, Placebo
- Biological · Drug
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- 12 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Hemet, California • Menifee, California • Rockford, Illinois + 1 more
- Conditions
- Childhood Obesity
- Interventions
- Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo
- Behavioral · Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- High Cardiovascular Risk, Hypertension
- Interventions
- Zilebesiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 139
- States / cities
- Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
- Conditions
- Osteoarthritis, Hip
- Interventions
- Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
- Procedure · Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo
- Drug
- Lead sponsor
- Janssen Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more
- Conditions
- Early Rheumatoid Arthritis
- Interventions
- Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
- Biological · Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
- Conditions
- Hypochondroplasia
- Interventions
- Vosoritide, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Alopecia Areata
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- Emma Guttman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
- Drug
- Lead sponsor
- Tibotec BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
- Conditions
- Severe Asthma
- Interventions
- Verekitug, Placebo
- Drug
- Lead sponsor
- Upstream Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 28
- States / cities
- Bakersfield, California • Northridge, California • Upland, California + 21 more
- Conditions
- EoE, Eosinophilic Esophagitis
- Interventions
- Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more
- Conditions
- Myasthenia Gravis
- Interventions
- TAK-079, TAK-079 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
- Conditions
- Angioedema
- Interventions
- ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
- Drug
- Lead sponsor
- Bernstein, Jonathan A., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
- Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- Chronic Weight Management
- Interventions
- ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- LY2189102, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more